Physician profile
Patrick Alan Proctor
NPI 1477999605
$846.62
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.18 · 2020: $72.10 · 2021: $208 · 2022: $220 · 2023: $180 · 2024: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $297.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $152.30 | 2022-2023 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $134.43 | 2021-2022 | |
| Novo Nordisk INC | $132.32 | 2022-2024 | Rybelsus, Ozempic |
| Amgen INC. | $115.40 | 2019-2021 | |
| Angiodynamics, INC. | $87.38 | 2023 | Auryon Laser System 100-120 Vac |
| Merck Sharp & Dohme LLC | $46.68 | 2021-2022 | |
| Abbott Laboratories | $40.04 | 2021-2023 | Mitraclip |
| Pfizer INC. | $33.68 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $30.59 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $23.99 | 2019-2020 | |
| Acutus Medical, INC. | $21.87 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $19.25 | 2023 | Camzyos |
| Lemaitre Vascular, INC. | $8.69 | 2023 | Artegraft Vascular Graft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Proctor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.